Los Angeles Capital Management LLC bought a new position in DaVita Inc. (NYSE:DVA) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 3,989 shares of the company’s stock, valued at approximately $464,000.
Several other hedge funds also recently added to or reduced their stakes in the company. FORA Capital LLC purchased a new stake in DaVita during the second quarter valued at $36,000. FinTrust Capital Advisors LLC raised its stake in DaVita by 35.8% during the second quarter. FinTrust Capital Advisors LLC now owns 349 shares of the company’s stock valued at $42,000 after purchasing an additional 92 shares in the last quarter. Financial Insights Inc. purchased a new stake in DaVita during the second quarter valued at $48,000. Parisi Gray Wealth Management purchased a new stake in DaVita during the second quarter valued at $50,000. Finally, Eubel Brady & Suttman Asset Management Inc. purchased a new stake in DaVita during the second quarter valued at $54,000. 86.54% of the stock is currently owned by hedge funds and other institutional investors.
A number of research firms recently issued reports on DVA. Truist upped their price target on shares of DaVita from $114.00 to $125.00 and gave the company a “hold” rating in a research note on Wednesday, January 5th. Royal Bank of Canada cut their price objective on shares of DaVita from $113.00 to $111.00 and set a “sector perform” rating on the stock in a research report on Friday, October 29th. Deutsche Bank Aktiengesellschaft cut their price objective on shares of DaVita from $164.00 to $150.00 and set a “buy” rating on the stock in a research report on Wednesday, November 17th. Truist Securities boosted their price objective on shares of DaVita from $114.00 to $125.00 and gave the company a “hold” rating in a research report on Wednesday, January 5th. Finally, Zacks Investment Research upgraded shares of DaVita from a “sell” rating to a “hold” rating and set a $121.00 price objective on the stock in a research report on Tuesday, January 4th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and one has issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $130.13.
NYSE DVA opened at $116.32 on Friday. The company’s 50-day moving average price is $106.73 and its 200-day moving average price is $116.28. The company has a current ratio of 1.62, a quick ratio of 1.58 and a debt-to-equity ratio of 6.60. The stock has a market cap of $11.85 billion, a PE ratio of 13.54, a PEG ratio of 1.15 and a beta of 1.24. DaVita Inc. has a 12 month low of $94.38 and a 12 month high of $136.48.
DaVita (NYSE:DVA) last posted its quarterly earnings results on Thursday, October 28th. The company reported $2.36 EPS for the quarter, topping the Zacks’ consensus estimate of $2.26 by $0.10. The firm had revenue of $2.94 billion for the quarter, compared to analysts’ expectations of $2.91 billion. DaVita had a net margin of 8.33% and a return on equity of 67.99%. The business’s revenue for the quarter was up .5% on a year-over-year basis. During the same period in the prior year, the business posted $1.80 earnings per share. As a group, sell-side analysts forecast that DaVita Inc. will post 8.89 earnings per share for the current year.
DaVita Company Profile
DaVita, Inc engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure.
Featured Article: How can investors invest in the Euro STOXX 50 Index?
Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA).
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.